Zhang Feng, Shao Yong-fu, Gao Ji-dong, Xu Yang, Liu Guo-ting, Xu Li-bin, Wu Zhi-yuan, Gao Wen-hong, Sun Zong-tang
Hepatic Surgery Centre, Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Zhonghua Wai Ke Za Zhi. 2007 Nov 1;45(21):1482-4.
To identify the association strength of the prevalence of HBeAg, covalently closed circular DNA (cccDNA) and 1762/1764 nucleotide mutations of hepatitis B virus (HBV) with the occurrence of hepatocellular carcinoma (HCC) in Qidong high risk male cohort.
A cohort of 377 middle aged HBV infected men in Qidong was followed from January 1989 to December 2002. Incident HCC cases were carefully registered. A matched case-controlled study was conducted on 32 pairs of inherent HCC cases with their matched non-HCC controls. Serum HBeAg was measured by ELISA. cccDNA was detected by primer selected PCR. 1762/1764 nucleotide mutations of HBV was identified by PCR of X gene segment spanning the mutation region. Standard statistical comparison between the prevalence of each HBV marker in HCC versus in control group provided the odds ratio with P value to evaluate its association strength with HCC occurrence.
Serum HBeAg prevalence was 53.1% (17/32) in HCC group versus and 15.6% (5/32) in controls (OR = 6.12, P < 0.01). Prevalence of serum cccDNA was detected in 62.5% (21/32) of HCC cases but in 25.0% (8/32) of controls (OR = 5.73, P < 0.01). Sequence of detected cccDNA was repeatedly found to be over 90% homologous with HBV. However, the mutation rate of nucleotide 1762/1764 was not found to be statistically higher in the HCC group versus its controls (OR = 1.54, P = 0.425).
The Qidong male case-controlled cohort had shown that serum HBeAg and cccDNA prevalence were tightly associated with hepatocellular carcinoma occurrence in HBV infected men. These biomarkers may have predictive value in earlier diagnosis and therapeutic effect monitoring.
确定启东高危男性队列中乙肝病毒(HBV)e抗原(HBeAg)、共价闭合环状DNA(cccDNA)及1762/1764核苷酸突变的流行率与肝细胞癌(HCC)发生之间的关联强度。
对1989年1月至2002年12月期间启东377名中年HBV感染男性队列进行随访。仔细记录新发HCC病例。对32对原发性HCC病例及其匹配的非HCC对照进行配对病例对照研究。采用酶联免疫吸附测定法(ELISA)检测血清HBeAg。通过引物选择PCR检测cccDNA。通过跨越突变区域的X基因片段PCR鉴定HBV的1762/1764核苷酸突变。HCC组与对照组中各HBV标志物流行率的标准统计学比较提供比值比及P值,以评估其与HCC发生的关联强度。
HCC组血清HBeAg流行率为53.1%(17/32),对照组为15.6%(5/32)(比值比=6.12,P<0.01)。62.5%(21/32)的HCC病例检测到血清cccDNA,而对照组为25.0%(8/32)(比值比=5.73,P<0.01)。检测到的cccDNA序列多次发现与HBV的同源性超过90%。然而,未发现HCC组中1762/1764核苷酸的突变率在统计学上高于其对照组(比值比=1.54,P=0.425)。
启东男性病例对照队列表明,血清HBeAg和cccDNA流行率与HBV感染男性肝细胞癌的发生密切相关。这些生物标志物可能在早期诊断和治疗效果监测中具有预测价值。